Patents Assigned to Scidose, LLC
-
Publication number: 20190336570Abstract: Liquid vancomycin containing compositions having extended shelf life are disclosed. The compositions contain vancomycin or a pharmaceutically acceptable salt thereof, a polyol such as glycerol, and lactic acid or a lactate. The compositions are ready to use and easily transferred into larger parenteral solutions prior to administration to patients in need thereof.Type: ApplicationFiled: July 16, 2019Publication date: November 7, 2019Applicant: SciDose, LLCInventors: Nagesh R. Palepu, Philip Christopher Buxton
-
Patent number: 10376559Abstract: Liquid vancomycin containing compositions having extended shelf life are disclosed. The compositions contain vancomycin or a pharmaceutically acceptable salt thereof, a polyol such as glycerol, and lactic acid or a lactate. The compositions are ready to use and easily transferred into larger parenteral solutions prior to administration to patients in need thereof.Type: GrantFiled: January 13, 2017Date of Patent: August 13, 2019Assignee: SCIDOSE, LLCInventors: Nagesh R. Palepu, Philip Christopher Buxton
-
Patent number: 9616098Abstract: Vancomycin-containing compositions substantially free of precipitation after at least about 12 months of storage at refrigerated or ambient conditions are disclosed. The compositions include vancomycin or a pharmaceutically acceptable salt thereof; a polar solvent including propylene glycol, polyethylene glycol and mixtures thereof; lactic acid, a lactate salt, or mixtures thereof; and optionally, a pH adjuster in an amount sufficient to maintain a pH of the compositions at from about 3 to about 8.Type: GrantFiled: May 30, 2014Date of Patent: April 11, 2017Assignee: SciDose, LLCInventor: Nagesh R. Palepu
-
Patent number: 9238037Abstract: Long term storage stable budesonide-containing solutions are disclosed. The solutions can include budesonide or a pharmaceutically acceptable salt thereof, cromolyn sodium, antioxidizing agent, benzoic acid, and a pharmaceutically acceptable fluid including propylene glycol and water. Kits including the long term storage stable budesonide-containing solutions and methods of treating ulcerative colitis are also disclosed.Type: GrantFiled: July 8, 2014Date of Patent: January 19, 2016Assignee: SciDose, LLCInventors: Nagesh R. Palepu, Philip Christopher Buxton
-
Patent number: 9180088Abstract: Fulvestrant formulations suitable for intramuscular injection at concentration in excess of 40 mg/ml in the absence of castor oil and castor oil derivatives are disclosed.Type: GrantFiled: March 5, 2009Date of Patent: November 10, 2015Assignee: SCIDOSE, LLCInventor: Nageswara R. Palepu
-
Patent number: 8912228Abstract: Pharmaceutical formulations comprising docetaxel or a pharmaceutically acceptable salt thereof, one or more solubilizers, ?-lipoic acid, TPGS, one or more hydrotropes, and optionally one or more agents having a pKa of about 3 to about 6. The pharmaceutical formulations are stable and substantially free of excipients that can cause severe side effects and maintains chemical stability during storage. The pharmaceutical formulations are ready to be combined with an infusion solution for administration to patients in need thereof. Methods of treating patients in need thereof comprise administering the pharmaceutical formulations combined with an infusion solution.Type: GrantFiled: August 10, 2011Date of Patent: December 16, 2014Assignee: Scidose LLCInventor: Nageswara R. Palepu
-
Patent number: 8809308Abstract: Long term storage stable budesonide-containing solutions are disclosed. The solutions can include budesonide or a pharmaceutically acceptable salt thereof, cromolyn sodium, antioxidizing agent, benzoic acid, and a pharmaceutically acceptable fluid including propylene glycol and water. Kits including the long term storage stable budesonide-containing solutions and methods of treating ulcerative colitis are also disclosed.Type: GrantFiled: November 11, 2013Date of Patent: August 19, 2014Assignee: SciDose, LLCInventors: Nagesh R. Palepu, Philip Christopher Buxton
-
Publication number: 20130267489Abstract: Long term storage stable fulvestrant-containing compositions are disclosed. The compositions can include fulvestrant; a solvent selected from dimethyl sulfoxide (DMSO), glycofurol, N-methyl pyrrolidone, and mixtures thereof; an oil mixture selected from a mixture of caprylic and capric triglycerides, a mixture of caprylic, capric and linoleic triglycerides, a mixture of caprylic, capric and succinic triglycerides, and a mixture of propylene glycol dicaprylate and propylene glycol dicaprate; and a sustained release member selected from benzyl benzoate, dihydrolipoic acid, benzyl alcohol and lipoic acid. The fulvestrant-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 24 months of storage at a temperature of from about 5° C. to about 25° C.Type: ApplicationFiled: April 8, 2013Publication date: October 10, 2013Applicant: SciDose, LLCInventors: Bulusu Bhanu Teja, Nagesh R. Palepu
-
Patent number: 8541465Abstract: Formulations comprising docetaxel or a salt thereof in combination with ?-lipoic acid and/or dihydrolipoic acid and/or salts thereof in narrow concentration ranges have improved stability as concentrate liquid formulations and permit longer times between dilution from higher concentrations through completion of infusions prepared therefrom allowing for lesser waste and more efficient use of personnel in infusion preparation.Type: GrantFiled: October 19, 2009Date of Patent: September 24, 2013Assignee: SciDose, LLCInventor: Nageswara R. Palepu
-
Patent number: 8476310Abstract: Pharmaceutical formulations comprising docetaxel, solubilizer, and ?-lipoic acid, wherein the formulation is substantially free of polysorbates and polyethoxylated castor oil. The solubilizer may comprise glycofurol, acetic acid, benzyl alcohol, or ethanol. The ?-lipoic acid, at certain concentrations, may impart stability and prevent degradation of docetaxel while the formulations are in storage. The formulations may be combined with a diluent, which comprises one or more hydrotropes such as tocopherol polyethylene glycol succinate and polyethylene glycol. The formulations combined with the diluent also exhibit stability after storage. Methods of administering docetaxel comprise preparing the formulation comprising docetaxel, solubilizer, and ?-lipoic acid; mixing the formulation with a diluent; diluting the resulting formulation in saline, water for injection, or the like; and then injecting the formulations into patients in need thereof.Type: GrantFiled: March 11, 2010Date of Patent: July 2, 2013Assignee: SciDose LLCInventor: Nagesh Palepu
-
Patent number: 8158152Abstract: A lyophilization process which comprises dissolving a material in one or more solvents for said material to form a solution; forcing said material at least partially out of solution by combining the solution and a non-solvent for the material, which non-solvent is miscible with the solvent or solvents used and wherein said non-solvent is volatilizable under freeze-drying conditions. In addition, for hydrophobic and/or lipophilic materials, the anti-solvent can be omitted, and the solution of the material in the solvent can be subjected directly to freeze drying. The lyophilizates can then be reconstituted with typical aqueous diluent in the case of hydrophilic materials. Hydrophobic and or lipophilic materials can be initially reconstituted with propylene glycol and/or polyethyleneglycol to form a high concentration solution therein and this is further diluted for use with a diluent of Intralipid, plasma, serum, or even whole blood.Type: GrantFiled: November 18, 2005Date of Patent: April 17, 2012Assignee: SciDose LLCInventor: Nageswara R. Palepu
-
Publication number: 20110092579Abstract: Docetaxel containing formulations having TPGS and being substantially free or totally free of polysorbate surfactants are disclosed wherein stability is enhanced and hypersensitivity reactions are reduced.Type: ApplicationFiled: October 19, 2009Publication date: April 21, 2011Applicant: Scidose LLCInventor: Nageswara R. Palepu
-
Publication number: 20110092580Abstract: Formulations comprising docetaxel or a salt thereof in combination with ?-lipoic acid and/or dihydrolipoic acid and/or salts thereof in narrow concentration ranges have improved stability as concentrate liquid formulations and permit longer times between dilution from higher concentrations through completion of infusions prepared therefrom allowing for lesser waste and more efficient use of personnel in infusion preparation.Type: ApplicationFiled: October 19, 2009Publication date: April 21, 2011Applicant: Scidose LLCInventor: Nageswara R. Palepu
-
Publication number: 20100239669Abstract: Co-therapy of an anti-obesity agent, a statin, is disclosed along with fixed combinations thereof. Atorvastatin and orlistat are preferred as the various components.Type: ApplicationFiled: May 21, 2010Publication date: September 23, 2010Applicant: Scidose LLCInventor: Negeswara R. Palepu
-
Publication number: 20100234443Abstract: Co-therapy of an anti-obesity agent, a statin, is disclosed along with fixed combinations thereof. Atorvastatin and orlistat are preferred as the various components.Type: ApplicationFiled: May 21, 2010Publication date: September 16, 2010Applicant: Scidose LLCInventor: Nageswara R. Palepu
-
Patent number: 7772274Abstract: Pharmaceutical formulations comprising docetaxel, solubilizer, and ?-lipoic acid, wherein the formulation is substantially free of polysorbates and polyethoxylated castor oil. The solubilizer may comprise glycofurol, acetic acid, benzyl alcohol, or ethanol. The ?-lipoic acid, at certain concentrations, may impart stability and prevent degradation of docetaxel while the formulations are in storage. The formulations may be combined with a diluent, which comprises one or more hydrotropes such as tocopherol polyethylene glycol succinate and polyethylene glycol. The formulations combined with the diluent also exhibit stability after storage. Methods of administering docetaxel comprise preparing the formulation comprising docetaxel, solubilizer, and ?-lipoic acid; mixing the formulation with a diluent; diluting the resulting formulation in saline, water for injection, or the like; and then injecting the formulations into patients in need thereof.Type: GrantFiled: March 11, 2010Date of Patent: August 10, 2010Assignee: Scidose, LLCInventor: Nagesh Palepu